OGT and colonic neoplasm: (2021) demonstrate that a combination of TRAIL and OSMI-1 (OGT inhibitor) enhances TRAIL-induced apoptosis in colon cancer cells and xenograft tumors by lowering the activity of Inhibitory κB Kinase β (IKKβ) and inhibition of downstream NF-κB pro-survival signaling (73) (Figure 1).